Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

NCT05589896 is registered in ClinicalTrials.gov with Ossium Health, Inc. as lead sponsor.

NCT NCT05589896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05589896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Lead sponsor
Ossium Health, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 16, 2024
Completion date
May 31, 2029
Enrollment
12 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, chronic myeloid leukemia (cml), cll (chronic lymphocytic leukemia), cutaneous t cell lymphomas (ctcl), hodgkins lymphoma, mds (myelodysplastic syndrome), non-hodgkin lymphomas